Diploma PLC (LON:DPLM – Get Rating) has earned a consensus rating of “Hold” from the seven research firms that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is GBX 3,190 ($39.33).
Several brokerages have commented on DPLM. Royal Bank of Canada restated an “underperform” rating and issued a GBX 2,550 ($31.44) price objective on shares of Diploma in a report on Thursday, March 24th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of Diploma in a report on Thursday, April 7th. Berenberg Bank lifted their target price on shares of Diploma from GBX 3,200 ($39.45) to GBX 3,360 ($41.43) and gave the company a “buy” rating in a report on Wednesday. Peel Hunt reiterated an “add” rating and set a GBX 3,500 ($43.15) target price on shares of Diploma in a report on Wednesday, January 19th. Finally, Barclays restated an “overweight” rating and issued a GBX 3,290 ($40.56) price objective on shares of Diploma in a report on Tuesday, April 12th.
Shares of DPLM opened at GBX 2,604 ($32.10) on Friday. The company has a debt-to-equity ratio of 47.04, a current ratio of 1.67 and a quick ratio of 0.78. Diploma has a one year low of GBX 2,384 ($29.39) and a one year high of GBX 3,504 ($43.20). The company has a 50-day simple moving average of GBX 2,676.04 and a two-hundred day simple moving average of GBX 2,899.45. The firm has a market capitalization of £3.25 billion and a PE ratio of 46.58.
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, rest of Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies clinical diagnostics instrumentation and products, consumables, specialty surgical devices, and related consumables and services to public hospitals, private clinics, pathology laboratories, scientific research, and medical segments; surgical equipment for hospital operating rooms; and distributes laboratory diagnostics, specialty medical devices, devices, equipment, and patient monitoring technologies used in operating theatres, as well as medically supervised nutrition.
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Diploma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diploma and related companies with MarketBeat.com's FREE daily email newsletter.